RESUMO
INTRODUCTION: Although plerixafor in association with granulocyte colony-stimulating factor (G-CSF) can improve mobilization and collection of hematopoietic stem cells (HSC) by leukapheresis, cost may limit its clinical application. The present study systematically reviews economic evaluations of plerixafor plus G-CSF usage compared to G-CSF alone and compares different strategies of plerixafor utilization in multiple myeloma and lymphoma patients eligible for autologous HSC transplantation. AREAS COVERED: Relevant economic evaluations, partial or complete, were searched on PubMed, Embase, LILACS, and Cochrane Central Register of Controlled Trials for a period ending 30 June 2021. This systematic review was reported following the PRISMA Statement. Six economic evaluations were included, considering the use of upfront or just-in-time plerixafor compared to G-CSF alone or other plerixafor strategies. Most comparisons showed both increased cost and health benefits with the addition of plerixafor. Most analyses favored just-in-time plerixafor compared to upfront plerixafor, with a probable preference for broader cutoffs for just-in-time plerixafor initiation. EXPERT OPINION: Plerixafor is a potentially cost-effective technology in the mobilization of HSC in patients with multiple myeloma and lymphomas eligible for autologous HSC transplantation. There is a decreased number of leukapheresis sessions and remobilizations and a higher yield of CD34+ cells.
Assuntos
Transplante de Células-Tronco Hematopoéticas , Compostos Heterocíclicos , Linfoma , Mieloma Múltiplo , Humanos , Mieloma Múltiplo/terapia , Mobilização de Células-Tronco Hematopoéticas , Leucaférese , Análise Custo-Benefício , Transplante Autólogo , Compostos Heterocíclicos/metabolismo , Linfoma/terapia , Linfoma/metabolismo , Células-Tronco Hematopoéticas/metabolismo , Células-Tronco Hematopoéticas/patologia , Fator Estimulador de Colônias de Granulócitos , Benzilaminas/metabolismoRESUMO
Objetivos: avaliar o efeito da infusão das folhas da planta Averrhoa carambola nos níveis glicêmicos de pacientes com diabetes mellitus tipo 2. Métodos: este ensaio clínico estudou 22 pacientes, divididos em grupo teste (11 pacientes que fizeram uso do chá das folhas de Averrhoa carambola) e grupo controle (11 pacientes sem uso do chá), que foram acompanhados durante um período de três meses. Para avaliar os níveis glicêmicos, foi feita dosagem sanguínea em intervalos de 15 dias. Resultados: após três meses, os níveis de glicose sanguínea do grupo que ingeriu o chá das folhas de Averrhoa carambola não diferiram dos níveis do grupo teste. Durante o período da pesquisa a função renal foi monitorada através da dosagem sérica de creatinina, que se mostrou inalterada nos dois grupos. Conclusões: não foram detectados efeitos da ingestão de infusão das folhas da planta Averrhoa carambola nos níveis glicêmicos de pacientes com diabetes mellitus tipo 2.
Aims: To evaluate the effect of Averrhoa carambola infusion in blood glucose levels of patients with Diabetes Mellitus Type 2. Methods: This clinical trial studied 22 patients, divided in test group (11 patients who drank the tea of Averrhoa carambola leaves) and control group (11 patients who did not drink the tea), which were monitored over a period of three months. To analyze the blood glucose levels, blood dosage was done every 15 days. Results: After three months, the blood glucose levels in the group that ingested the tea of leaves of Averrhoa carambola did not differ from those of the test group. During the trial period the renal function was monitored by seric creatinine dosage, which remained unchanged in both groups. Conclusions: This study did not detect effects of the tea of Averrhoa carambola leaves on blood glucose levels of patients with diabetes mellitus Type 2.